Cervical Cancer Screening

Overview

Cervical cancer screening aims to detect precancerous lesions (cervical intraepithelial neoplasia, CIN) and early invasive cancer before symptoms develop. The dramatic decline in cervical cancer mortality over decades is largely attributable to widespread Pap smear screening. HPV (human papillomavirus) is the fundamental etiologic factor for cervical cancer, and HPV-based testing has become central to modern screening strategies.

Screening Methods

Method	Description
Cytology (Pap smear)	Samples cervical cells and examines for abnormal morphology
Primary HPV testing	Tests directly for high-risk HPV strains; preferred by current guidelines
Co-testing	HPV test + cytology together; higher sensitivity than either alone

Current Guidelines

American Cancer Society (ACS) 2020 — Preferred Strategy

(Cervical Cancer Screening for Individuals at Average Risk, p. 1)

Age Group	Recommended Approach	Interval
< 25 years	No screening	—
25–65 years	Primary HPV testing (preferred)	Every 5 years
25–65 years	Co-testing (HPV + cytology) if primary HPV unavailable	Every 5 years
25–65 years	Cytology alone if above unavailable	Every 3 years
> 65 years	Discontinue if adequate prior negative screening & no CIN2+ in past 25 years	—

Co-testing and cytology-alone are considered acceptable but transitional — to be phased out as primary HPV testing becomes universally accessible.

Harrison's Principles (21st Ed., p. 1994) — Traditional Framework

Pap testing begins at age 21, regardless of sexual debut
Interval: every 3 years
From age 30 onward: HPV testing added (with or without Pap); if normal, interval extends to 5 years

Note: The ACS 2020 guideline updates the start age to 25 and makes primary HPV testing the preferred strategy from age 25. The traditional age-21 start (per older USPSTF/ACOG-aligned guidance) and the newer ACS recommendation coexist; clinicians should follow the most current local/institutional guidelines.

Key Principles

Screening before age 21 (or 25 per ACS): More harm than benefit — HPV infections are common, transient, and unlikely to progress in young individuals; overdiagnosis leads to unnecessary colposcopy and overtreatment.
More frequent screening adds little benefit but increases harms: unnecessary procedures and overtreatment of transient lesions (Harrison's, p. 1994).
Vaccination status does not change screening recommendations — vaccinated individuals should continue routine screening per the same schedule.
Post-hysterectomy (for benign indications, with no cervix remaining): screening can be discontinued.

When to Stop Screening

Discontinue at age > 65 if ALL of the following are met:

No history of CIN2 or more severe disease in the past 25 years
Documented adequate negative prior screening in the past 10 years

Abnormal Results — Next Steps

Positive HPV and/or abnormal cytology results should be managed per the 2019 ASCCP (American Society for Colposcopy and Cervical Pathology) risk-based management consensus guidelines, which stratify follow-up by immediate and 5-year risk of CIN3+:

Low risk: Repeat screening at extended interval
Intermediate risk: 1-year follow-up
High risk: Colposcopy (with or without biopsy)
Immediate concern for invasion: Expedited evaluation/referral

Special Populations

Population	Guidance
Immunocompromised (HIV+, transplant)	More frequent screening; some guidelines recommend annual Pap
DES (diethylstilbestrol) exposure in utero	Annual screening; colposcopy at initiation
Post-treatment for CIN2/3	Continued surveillance for 25 years after treatment
Pregnancy	Routine screening should not be deferred; colposcopy acceptable, endocervical curettage avoided

Summary Algorithm

Age < 25 → No screening
Age 25–65 → Primary HPV test every 5 years (preferred)
              OR Co-test every 5 years
              OR Cytology alone every 3 years
Age > 65 → Stop if criteria met (adequate prior screening, no recent CIN2+)
Abnormal → Risk-stratify per ASCCP 2019 guidelines → Repeat / 1-yr follow-up / Colposcopy

Sources: Harrison's Principles of Internal Medicine, 21st Ed. (p. 1994); ACS Cervical Cancer Screening for Individuals at Average Risk, 2020 (p. 1).

This is a shared conversation. Sign in to Orris to start your own chat.